BioTuesdays

Category - Markets

Eiger BioPharmaceuticals Logo
Markets

Roth starts Eiger Biopharma at buy

Roth Capital Partners initiated coverage of Eiger Biopharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $35 price target. The stock closed at $11.65 on Oct. 18. Analyst Michael Higgins writes that the company is...

October 19, 2017
Madrigal Pharmaceuticals
Markets

Roth starts Madrigal Pharma at buy

Roth Capital Partners launched coverage of Madrigal Pharmaceuticals (NASDAQ:MDGL) with a “buy” rating and a 12-month price target of $62. The stock closed at $47.52 on Oct. 18. “Our rating on Madrigal shares is based on...

October 19, 2017
Galectin Therapeutics
Markets

Roth starts Galectin at buy

Roth Capital Partners initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and a 12-month price target of $8. The stock closed at $2.51 on Oct. 18. “Our rating on Galectin shares is based on our...

October 19, 2017
Ignyta
Markets

Ladenburg ups Ignyta price target to $31

Ladenburg Thalmann raised its price target for Ignyta (NASDAQ:RXDX) to $31 from $20.25 based on expectations for entrectinib to be first line therapy for ROS1+ non-small cell lung cancer (NSCLC). The stock was changing...

October 18, 2017
Audentes
Markets

WB starts Audentes Therapeutics at OP

William Blair initiated coverage of Audentes Therapeutics (NASDAQ:BOLD) with an “outperform” rating and $35 fair value estimate. The stock closed at $25 on Oct. 16. Analyst Raju Prasad writes that the company is taking...

October 17, 2017
Ardelyx
Markets

Leerink resumes coverage of Ardelyx at OP

Leerink resumed coverage of Ardelyx (NASDAQ:ARDX) with an “outperform” rating and $13 price target. The stock closed at $6.40 on Oct. 16. Analyst Seamus Fernandez writes that in the last nine months, the clinical...

October 17, 2017
Flex Pharma
Markets

Flex Pharma starts Phase 2 CMT trial

Flex Pharma (NASDAQ:FLKS) has initiated a Phase 2 double-blinded, parallel design trial in the U.S., known as COMMIT, to evaluate FLX-787, its co-activator of TRPA1 and TRPV1, in patients with Charcot-Marie-Tooth, who...

October 16, 2017
KalVista Pharmaceuticals Logo
Markets

BTIG ups KalVista price target to $27

BTIG raised its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $27 from $18 after the company inked a multifaceted collaboration with Merck (NYSE:MRK) last week. The stock closed at $9.74 on Oct. 13...

October 16, 2017
BioTime
Markets

BioTime prices $25-million stock offering

BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million. The offering is expected to close on Oct. 17. BioTime also granted...

October 13, 2017
Calithera Biosciences
Markets

WB starts Calithera at OP

William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5. “Continued clinical catalysts and a clear development path with the company’s...

October 6, 2017